8-K - Corbus Pharmaceuticals Holdings, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Corbus Pharmaceuticals Holdings, Inc. reported Q4 and full year 2025 financial results, including a Q4 net loss of $20.6 million ($1.25 per share) and cash of $163.3 million extending runway into 2028, alongside promising CRB-701 oncology data and CRB-913 obesity trial updates with key readouts expected in 2026.

Key Takeaways

1Q4 2025 net loss $20.6 million or $1.25 per basic and diluted share vs $9.5 million or $0.78 per share in Q4 2024

2Full year 2025 net loss $78.5 million or $5.90 per share vs $40.2 million or $3.68 per share in 2024

3Cash, cash equivalents, and investments $163.3 million as of December 31, 2025, funding operations into 2028

4CRB-701 unconfirmed ORR at 3.6 mg/kg: HNSCC 47.6%, cervical cancer 37.5%, bladder 55.6% per ESMO 2025 data

5CRB-913 14-day weight loss 2.9% placebo-adjusted at 150 mg/day with favorable GI safety in Phase 1a

6Completed $75 million public offering in Q4 2025

7CRB-913 12-week study (n=240) completion expected summer 2026; CRB-701 mid-2026 monotherapy data

Current Report Details

Event Type

Financial Results

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

Results of Operations and Financial Condition. Corbus Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on March 9, 2026, disclosing financi

Financial Results

7.01

Regulation FD Disclosure. See “Item 2.02 Results of Operations and Financial Condition” above. The Company also updated its presentation used by management to d

Regulation Fd

9.01

Financial Statements and Exhibits. (d) The following exhibit is furnished with this report: Exhibit No. Description 99.1 Press Release issued by Corbus Pharmace

Exhibits Only

Source Document

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2